Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.45 |
| ▸ | CNR1 | P21554 | 11/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | PRKCB | P05771 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4054311 | 0.84 | CNR1 (0.38) | CNR2CNR1GSK3BALDH1A1MAPT | |
| SCHEMBL4054906 | 0.84 | CNR1 (0.49) | CNR2CNR1PRKCBGSK3BALDH1A1 | |
| SCHEMBL4052413 | 0.77 | CFTR (0.44) | CNR2CNR1CFTRALDH1A1MAPT | |
| SCHEMBL20688030 | 0.76 | CNR2 (0.51) | CNR2CNR1CFTRPRKCBGSK3B | |
| SCHEMBL22252332 | 0.75 | CNR2 (0.53) | CNR2CNR1CFTRPRKCBGSK3B | |
| SCHEMBL9237227 | 0.75 | CDC25A (0.49) | CNR2CNR1 | |
| SCHEMBL4054224 | 0.74 | CNR1 (0.43) | CNR2CNR1GSK3BMAPT | |
| SCHEMBL4054387 | 0.74 | DRD4 (0.39) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4055361 | 0.73 | CNR1 (0.37) | CNR2CNR1ALDH1A1MAPTMAPK1 | |
| SCHEMBL4054230 | 0.73 | ALDH1A1 (0.38) | CNR2CNR1ALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622480-B2 | Selective H1 histamine receptor antagonists; bronchial asthma, allergic rhinitis, conjunctivitis, dermatitis, urticaria and other allergic diseases; e.g. 3-(4-[1-(2-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]piperidin-1-ylmethyl)benzoic acid | LABORATORIOS ALMIRALL S.A. (ES) | 2009-11-24 | — | — | US | disclosed |
| US-20050176751-A1 | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176751-A1 | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | HRH2, HRH1, HRH4 | CNR2 88/4885CNR1 99/4885CFTR 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.